Epirus, AnaBios deal

Epirus (formerly Zalicus Inc.) granted CRO AnaBios exclusive, worldwide rights to develop and commercialize the biotech’s preclinical-stage sodium channel modulator portfolio, including IP and related pipeline assets. The products include compounds that block the Nav1.7 (SCN9A) and Nav1.8 ( PN3; SCN10A) sodium channels and are in preclinical testing to treat pain. Zalicus is eligible for up to $17.2 million in clinical and regulatory milestones and up to 12% of net sales of products resulting from the license. ...